Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study)

• Published in: International journal of clinical oncology Vol. 27; no. 8; pp. 1300 - 1308
• Main Authors: Ishiyama, Shun, Yamada, Takeshi, Nakamura, Masato, Enomoto, Masanobu, Sugimoto, Kiichi, Yokomizo, Hajime, Kosugi, Chihiro, Ohta, Ryo, Ishimaru, Kei, Sonoda, Hiromichi, Ishibashi, Keiichiro, Kuramochi, Hidekazu, Yoshida, Yoichiro, Ichikawa, Daisuke, Hirata, Keiji, Yoshida, Hiroshi, Hashiguchi, Yojiro, Ishida, Hideyuki, Koda, Keiji, Katsumata, Kenji, Sakamoto, Kazuhiro
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.08.2022; Springer Nature B.V
• Subjects: Adverse events; Cancer; Cancer Research; Cancer therapies; Chemotherapy; Colorectal cancer; Colorectal carcinoma; Disease control; Inhibitor drugs; Liver diseases; Medicine; Medicine & Public Health; Metastases; Metastasis; Oncology; Original Article; Patients; Surgical Oncology; Survival; Targeted cancer therapy; Regorafenib; Japanese patients; Dose-escalation; Colorectal cancer

Background Regorafenib significantly improves overall survival in previously treated metastatic colorectal cancer patients. However, various toxicities, such as hand-foot skin reaction (HFSR), fatigue, and liver dysfunction have limited the use of regorafenib. These toxicities appear soon after trea...